State Government / Indiana / Legislation / SB 262
Sets forth the circumstances in which a dispenser is not required to transmit certain information to the INSPECT program (program). Requires an opioid treatment program to, before reporting patient information to the program, comply with federal regulations in obtaining patient consent. Allows the board of pharmacy to disclose prescription drug monitoring program data to a representative of the Indiana department of health and the office of the secretary of family and social services for specified purposes.
Latest development · Mar 5, 2026
Public Law 133
Civixly topics
Source subjects
Document type
Primary sponsors are listed before cosponsors and other sponsoring entities.
Newest action first. Action language is supplied by the state source.
Public Law 133
Signed by the Governor
Signed by the Speaker
Signed by the President Pro Tempore
Signed by the President of the Senate
Senate concurred with House amendments; Roll Call 287: yeas 47, nays 0
Returned to the Senate with amendments
Motion to concur filed
Third reading: passed; Roll Call 312: yeas 94, nays 0
Second reading: ordered engrossed
Committee report: amend do pass, adopted
First reading: referred to Committee on Public Health
Referred to the House
House sponsor: Representative Goss-Reaves
Third reading: passed; Roll Call 127: yeas 48, nays 0
Cosponsors: Representatives Barrett, Ledbetter
Second reading: amended, ordered engrossed
Amendment #2 (Crider) prevailed; voice vote
Senator Charbonneau added as second author
Committee report: amend do pass, adopted
Authored by Senator Crider
First reading: referred to Committee on Health and Provider Services
0 comments
Loading comments...